"Black Canyon Bio (BCB) is developing novel products for treating cancer using our proprietary Specific Neo-Antigen Peptides (SNAPTM) Technology platform. SNAPTM Technology has product development applications across many cancers and other diseases. SNAPTM Technology was developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network. BCB's first two products, SNAPTM-Vac (a personalized cancer vaccine) and SNAPTM-TIL (a personalized cellular therapy), will start human clinical testing in 2024. The market for cancer vaccines and cellular therapies is expected to grow exponentially during the next decade."